This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly s.c. (subcutaneous, under the skin) injections to patients with active rheumatoid arthritis (RA) who are inadequate responders to anti-TNFa biologics and are on a stable background of methotrexate (MTX) therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01636817?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
